双特异性抗体研发商Ferrosa Therapeutics宣布获得350万美元种子融资，以推进针对炎症性贫血的首创双特异性抗体项目-动脉网

FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION

CISION 等信源发布 2026-04-23 19:57



可切换为仅中文







Novel bispecific antibody with a dual mechanism of action targeting anemia of inflammation in chronic kidney disease, autoimmune disease, and cancer

新型双特异性抗体，具有双重作用机制，靶向慢性肾病、自身免疫疾病和癌症相关的炎症性贫血

Experienced leadership and advisory team with deep expertise in antibody engineering, red blood cell biology, and nephrology

具有抗体工程、红细胞生物学和肾病学深厚专业知识的经验丰富的领导和顾问团队

Seed financing led by Forty51 Ventures

由Forty51 Ventures领投的种子轮融资

BASEL, Switzerland

瑞士巴塞尔

，

April 23, 2026

2026年4月23日

/PRNewswire/ -- Ferrosa Therapeutics AG ('FERROSA'), a Swiss biotechnology company developing a first-in-class bispecific antibody to treat anemia of inflammation, announced today a seed financing of USD 3.5 Million by founding investor Forty51 Ventures.

/PRNewswire/ -- 瑞士生物技术公司Ferrosa Therapeutics AG（“FERROSA”）正在开发一种用于治疗炎症性贫血的首创新型双特异性抗体，该公司今日宣布已获得创始投资者Forty51 Ventures 350万美元的种子轮融资。

FERROSA's lead program is a bispecific antibody designed to address key biological drivers of anemia of inflammation: cytokine-driven dysregulation of iron homeostasis that impairs erythropoiesis. The company's proprietary dual-mechanism approach combines two complementary clinically validated pathways to restore effective red blood cell production and normalize iron availability..

FERROSA的主导项目是一种双特异性抗体，旨在解决炎症性贫血的关键生物学驱动因素：细胞因子驱动的铁稳态失调，这种失调会损害红细胞生成。该公司专有的双重机制方法结合了两条互补的经过临床验证的途径，以恢复有效的红细胞生产并使铁的供应正常化。

Anemia of inflammation is a prevalent comorbidity in patients with chronic kidney disease, autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease, and many cancers. Existing treatments - including erythropoiesis-stimulating agents, intravenous iron, and blood transfusions - address symptoms rather than the underlying biology and carry safety risks.

炎症性贫血是慢性肾病、类风湿性关节炎和炎症性肠病等自身免疫性疾病以及多种癌症患者中普遍存在的合并症。现有的治疗方法（包括促红细胞生成剂、静脉注射铁剂和输血）针对症状而非潜在的生物学机制，并且存在安全风险。

There is a substantial unmet medical need for therapies that mechanistically correct iron restriction and restore effective erythropoiesis..

有一种重要的未满足医疗需求，即需要通过机制纠正铁限制并恢复有效的红细胞生成的疗法。

With the current financing, FERROSA will advance its preclinical program through antibody generation, bispecific engineering, and in vivo proof-of-concept studies in disease-relevant animal models.

通过当前的融资，FERROSA 将推进其临床前项目，包括抗体生成、双特异性工程以及在与疾病相关的动物模型中进行体内概念验证研究。

The company appointed co-founder Martin Stern, MD as the Chief Executive Officer. Martin Stern is a physician-scientist and board-certified hematologist with more than 25 years of combined academic and industry experience. He previously served as Chief Medical Officer at Numab Therapeutics, where he led clinical development of multispecific antibodies in oncology and immunology, and as CMO at Affivant Sciences.

公司任命联合创始人马丁·斯特恩医学博士为首席执行官。马丁·斯特恩是一位医生科学家，也是拥有超过25年学术和行业经验的认证血液科医生。他此前曾担任Numab Therapeutics的首席医学官，领导了肿瘤学和免疫学领域多特异性抗体的临床开发，并曾任Affivant Sciences的首席医学官。

Earlier in his career, he held senior positions at Roche Pharma Research and Early Development (pRED). Prior to that he was clinically active as a hematologist for more than a decade..

在他的职业生涯早期，他曾担任罗氏制药研究和早期开发（pRED）的高级职位。在此之前，他作为血液科医生临床工作了十多年。

Martin Stern commented: 'Anemia of inflammation remains one of the most prevalent yet inadequately treated complications across chronic diseases. Our bispecific approach has the potential to change how clinicians manage this condition – moving beyond symptomatic support toward correction of the underlying pathophysiology.

马丁·斯特恩评论道：“炎症性贫血仍然是跨慢性疾病中最普遍但治疗不足的并发症之一。我们的双特异性方法有可能改变临床医生管理这种疾病的方式——从仅仅提供症状支持转向纠正潜在的病理生理机制。”

I am excited to build FERROSA and bring this differentiated therapy to patients who need it.'.

我很兴奋能够打造FERROSA，并将这种差异化疗法带给需要它的患者。

FERROSA collaborates with leading experts in antibody engineering, red blood cell biology and nephrology. Dr. Beatriz Goyenechea, a recognized authority in antibody development and founder of StarBio International, serves as antibody development advisor. Prof. Stefano Rivella of the Children's Hospital of Philadelphia advises on preclinical disease models.

FERROSA与抗体工程、红细胞生物学和肾病学领域的领先专家合作。Beatriz Goyenechea博士是抗体开发的权威专家，也是StarBio International的创始人，担任抗体开发顾问。费城儿童医院的Stefano Rivella教授就临床前疾病模型提供指导。

Prof. Beatrice Goilav, Professor of Pediatrics at the Albert Einstein College of Medicine and Montefiore Hospital, and a leading clinical researcher in chronic kidney disease, serves as KOL and Clinical Advisor to the company..

阿尔伯特·爱因斯坦医学院和蒙特菲奥里医院的儿科教授、慢性肾病领域的领先临床研究员贝亚特丽斯·戈伊拉夫教授担任该公司的关键意见领袖（KOL）和临床顾问。

Forty51 Ventures is the seed investor of FERROSA and has been instrumental in the operational and financial set-up of the company. FERROSA was incorporated in Basel, Switzerland, a globally recognized hub for biotechnology and pharmaceutical innovation.

Forty51 Ventures 是 FERROSA 的种子投资者，在该公司的运营和财务设置方面发挥了重要作用。FERROSA 在瑞士巴塞尔成立，这里是全球公认的生物技术和医药创新中心。

ABOUT FERROSA THERAPEUTICS

关于费罗萨治疗学

Ferrosa Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2026. The company is developing a first-in-class bispecific antibody to treat anemia of inflammation across chronic kidney disease, autoimmune disease, and oncology. FERROSA's dual-mechanism approach aims to restore iron homeostasis and effective erythropoiesis by addressing the cytokine-driven dysregulation at the heart of this condition.

Ferrosa Therapeutics AG 于2026年由Forty51 Ventures在瑞士巴塞尔创立。该公司正在开发一种首创的双特异性抗体，用于治疗慢性肾病、自身免疫疾病和肿瘤学中的炎症性贫血。FERROSA的双重机制方法旨在通过解决这一疾病核心的细胞因子驱动失调，恢复铁稳态和有效的红细胞生成。

。

www.ferrosatx.com

ABOUT FORTY51 VENTURES

关于FORTY51风险投资公司

Forty51 Ventures is a venture capital firm with its core strategy focused on company formation in Biotech. Forty51 Ventures is a company builder leading first financing rounds of its growing portfolio of biotech companies

Forty51 Ventures是一家风险投资公司，其核心战略聚焦于生物技术领域的公司创建。Forty51 Ventures是一家公司建设者，主导其不断增长的生物技术公司组合的首轮融资。

www.forty51ventures.com

Contact:

联系人：

Martin Stern

马丁·斯特恩

Chief Executive Officer

首席执行官

Ferrosa Therapeutics AG

费罗萨治疗学股份公司

[email protected]

电子邮件地址